Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biome Australia Ltd ( (AU:BIO) ) just unveiled an update.
Biome Australia reported record sales for the second quarter and first half of FY26, with Q2 revenue reaching $6.48 million, up 40.9% on the prior corresponding period and 9.1% sequentially, despite Q2 typically being seasonally softer due to fewer December trading days and a pharmacy sector focus on gifting. Half-year FY26 revenue rose 40.2% to $12.42 million, underpinned by strong demand for the company’s clinically proven probiotic products, reinforcing its growth trajectory and indicating strengthening market adoption in its core complementary medicines and live biotherapeutics segments.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Limited is an Australian-based healthcare company that develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Founded in 2018, the company distributes its products locally and internationally, with a flagship range branded as Activated Probiotics, targeting health concerns such as low mood and sleep, bone health, iron malabsorption, mild eczema and IBS, primarily via practitioner-only distribution channels focused on educating health professionals about the systemic health effects of the gut microbiota.
Average Trading Volume: 198,691
Technical Sentiment Signal: Sell
Current Market Cap: A$92.38M
For a thorough assessment of BIO stock, go to TipRanks’ Stock Analysis page.